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Abstract. The adenoma-carcinoma sequence (ACS) and 
the serrated pathway are two distinct developmental routes 
leading to the formation of colorectal carcinoma. Recently, 
the doublecortin and CaM kinase-like-1 protein (DCLK1) has 
been reported to serve as an intestinal cancer stem cell marker 
and has been demonstrated to be overexpressed through the 
ACS; however, there is a lack of reports on the role of DCLK1 
in the serrated pathway. To clarify the correlation between 
DCLK1 protein expression and clinicopathological character-
istics of the serrated tumorigenic pathway, the present study 
used immunohistochemistry to examine the expression of 
DCLK1 in endoscopically resected samples of 62 serrated 
polyps [20 hyperplastic polyps (HPs), 16 traditional serrated 
adenomas (TSAs) and 26 sessile serrated adenoma-polyps 
(SSA/Ps)], as well as 20 non-serrated adenomas, 20 carcinoma 
in adenomas (CIAs) and 18 early pure colorectal carcinomas 
without any adenoma component (EPCs). Based on immunos-
taining score, high DCLK1 expression was detected in 20.0% 
of HPs (23.1% of microvesicular HPs and 14.3% of goblet cell 
HPs), 37.5% of TSAs, 7.7% of SSA/Ps, 80.0% of non-serrated 
adenomas, 75.0% of CIAs and 50.0% of EPCs. Negative or 
low DCLK1 expression was frequently observed in TSAs 
(P<0.005), SSA/Ps (P<0.00001) and EPCs (P<0.04) compared 
with non-serrated adenomas and CIAs. In addition, negative 
or low DCLK1 expression was significantly more frequent 
in SSA/Ps (92.3%) compared with TSAs (62.5%; P<0.05). 
Thus, the expression pattern of DCLK1 between the serrated 
pathway and ACS differed, indicating that DCLK1 expression 
may perform a secondary role in serrated tumorigenesis. In 
addition, the data indicates that EPCs may contain tumors 
derived from the serrated pathway as well as the ACS.
Introduction
Colorectal cancer (CRC) is among the most common types of 
malignancy in the United States, with a lifetime prevalence of 
~5% (1). It is proposed by the adenoma-carcinoma sequence 
(ACS) model that the carcinoma arises from a pre-existing 
adenoma (2). The serrated pathway to CRC formation, in which 
serrated polyps develop into cancer, has been proposed as an 
alternative route to colorectal carcinogenesis (3,4). According 
to the 2010 World Health Organization (WHO) classifica-
tion (5), serrated polyps may be categorized as hyperplastic 
polyps (HPs), sessile serrated adenoma-polyps (SSA/Ps) or 
traditional serrated adenomas (TSAs).
Doublecortin and CaM kinase-like-1 protein (DCLK1, also 
known as DCAMKL1) is a microtubule-binding member of 
the calmodulin-dependent kinase family that serves important 
roles in the regulation of cell differentiation, migration and 
apoptosis, and has also been proposed as a marker for intes-
tinal stem cells and cancer stem cells (6-9). In animal models 
with xenografted colonic or pancreatic tumors, silencing of 
the DCLK1 gene resulted in a decrease in tumor size (10-12). 
Although the precise tumor-promoting mechanism of DCLK1 
is yet to be determined, it has been demonstrated that reduced 
DCLK1 expression correlates with increased expression of 
tumor suppressor microRNAs (miRs), including miR-145, 
miR-200 and let-7a (11,12). Indeed, DCLK1 has been indi-
cated to function as an oncogene in several types of tumor, 
including CRC (13-15), pancreatic cancer (8), hepatocellular 
carcinoma (16), gastric cancer (17) and Barrett's adenocarci-
noma (18).
To the best of our knowledge, no previous study has compre-
hensively measured the expression of DCLK1 in serrated and 
non-serrated colorectal neoplasias. In the current study, to 
clarify the molecular and clinicopathological characteristics 
of the serrated tumorigenic pathway, immunohistochemistry 
was used to evaluate DCLK1 expression in 120 endoscopi-
cally-resected samples of serrated and non-serrated colorectal 
neoplasias.
Materials and methods
Patient samples. As described in our previous study on fragile 
histidine triad and cyclooxygenase-2 expression in serrated 
Expression of doublecortin and CaM kinase‑like‑1 
protein in serrated neoplasia of the colorectum
KEIKO MORIO,  KAZUO YASHIMA,  AKIHIRO TAMOTO,  KOHEI HOSODA,  SOHEI YAMAMOTO,   
TAKU IWAMOTO,  NAOKI UEDA,  YUICHIRO IKEBUCHI,  KOICHIRO KAWAGUCHI,  
KENICHI HARADA,  YOSHIKAZU MURAWAKI  and  HAJIME ISOMOTO
Division of Medicine and Clinical Science, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504, Japan
Received October 10, 2017;  Accepted October 30, 2017
DOI: 10.3892/br.2017.1017
Correspondence to: Dr Kazuo Yashima, Division of Medicine 
and Clinical Science, Faculty of Medicine, Tottori University, 
36-1 Nishicho, Yonago, Tottori 683-8504, Japan
E-mail: yashima@med.tottori-u.ac.jp
Key words: doublecortin and CaM kinase-like-1, serrated pathway, 
serrated adenoma-polyps, endoscopic resection
MORIO et al:  DCLK1 EXPRESSION IN SERRATED NEOPLASIA48
neoplasia (19), tumor specimens were obtained from 120 patients 
(90 males and 30 females; mean age, 66.1±11.5 years), who had 
undergone endoscopic resection at Tottori University Hospital 
(Tottori, Japan) between January 2009 and December 2014. 
The samples included 20 HPs, 16 TSAs and 26 sessile serrated 
adenoma/polyps (SSA/Ps), making a total of 62 serrated 
polyps, as well as 20 non-serrated adenomas, 20 carcinoma 
in adenomas (CIAs) and 18 early pure colorectal carcinomas 
without any adenoma component (EPCs). Patients with familial 
adenomatous polyposis (FAP), hereditary nonpolyposis CRC 
(HNPCC) or hyperplastic polyposis (HPP) were excluded 
from the study. Serrated lesions (HPs, SSAs and TSAs) were 
classified on the basis of WHO criteria (5). The 20 HPs were 
subdivided into ten microvesicular HPs (MVHPs) and ten goblet 
cell HPs (GCHPs). Non-serrated adenomas measuring >10 mm 
were used for the study. All histological types of CIAs and 
EPCs were well-differentiated adenocarcinomas. In addition, 
these neoplasms were confined to the mucosa or submucosa. 
Histological evaluations were performed according to the clas-
sification established by the Japanese General Rules for Clinical 
and Pathological Studies on Cancer of the Colon, Rectum and 
Anus (20). In the study, non-serrated adenoma samples corre-
sponded to low- or high-grade adenoma/dysplasia, and CIA 
and EPC samples of mucosa and submucosa corresponded 
to non-invasive carcinoma or intramucosal and submucosal 
carcinoma according to the Vienna classification system (21). 
Tumors were divided into polypoid, and flat or depressed groups 
on the basis of their morphological features. Flat and depressed 
tumors were defined as having endoscopically visibly flat or 
depressed mucosal lesions, with a height measuring >50% of 
their diameter (22). All other tumorous lesions in the colon 
were termed polypoid lesions. The clinical characteristics of the 
patients are reported in our previous study (19). All cases were 
de‑identified prior to analysis, and written informed consent 
was obtained from all patients. The study was approved by 
the Institutional Review Board of Tottori University and was 
conducted in accordance with the Declaration of Helsinki.
Immunohistochemical staining. Immunohistochemical 
staining was performed on paraffin‑embedded 5‑mm sections 
following fixation in 10% formalin overnight at room tempera-
ture. All sections were immunohistochemically stained with 
rabbit polyclonal anti-DCLK1 antibody (ab37994; dilution 
1:80; Abcam, Cambridge, MA, USA). Heat-induced epitope 
retrieval was performed in citrate buffer (pH 6.0) using 
a microwave oven at 99˚C. Primary antibody incubation 
was carried out overnight at 4˚C. Detection was performed 
with a Vectastain Elite ABC kit (Vector Laboratories, Inc., 
Burlingame, CA, USA) according to the manufacturer's 
instructions. As a negative control, the primary antibody 
was replaced with serum immunoglobulin G (GTX35035; 
GeneTex, Inc., Irvine, CA, USA) at the same dilution. A CIA 
sample from the total cohort exhibiting strong intensity immu-
nostaining for DCLK1, defined by the staining evaluation 
method of a previous study (13), was used as a positive control. 
For each specimen, at least five fields were viewed under a 
light microscope (magnification, x100; Olympus Corporation, 
Tokyo, Japan). Immunohistochemical staining of DCLK1 
expression was analyzed by two independent observers blinded 
to the clinical information.
Assessment of DCLK1 immunostaining. The extent (or 
proportion) of DCLK1 staining was scored as: 0 (<5% posi-
tive cells), 1 (5-30% positive cells), 2 (31-60% positive cells) 
or 3 (61-100% positive cells); the staining intensity was scored 
as: 0 (negative), 1 (mild), 2 (moderate) or 3 (strong), as previ-
ously described (13). The final score was determined from the 
combination of the staining intensity and proportion scores. 
Negative expression of DCLK1 was defined as a combined 
score of 0‑1; low expression was defined as a combined score 
of 2‑3; and high expression was defined as a combined score 
of 4-6 (13).
Statistical analysis. Statistical analysis was performed 
using the Fisher's exact test, χ² test with Yates' correction or 
Mann-Whitney U test. P<0.05 was considered to indicate statis-
tical significance. All statistical calculations were performed 
using Stat Flex (version 6.0; Artech Co., Ltd., Osaka, Japan).
Results
Clinicopathological features. The clinicopathological charac-
teristics of the patients are reported in our previous study (19).
DCLK1 expression in early colorectal neoplasms. The 
results of the immunohistochemical staining experiments 
are presented in Fig. 1 and Table I. High DCLK1 expres-
sion was detected in 20.0% of HPs (23.1% of MVHPs and 
14.3% of GCHPs), 37.5% of TSAs, 7.7% of SSA/Ps, 80.0% of 
non-serrated adenomas, 75.0% of CIAs and 50.0% of EPCs. 
Negative or low DCLK1 expression was frequently observed 
in HPs (P<0.0001), TSAs (P<0.005), SSA/Ps (P<0.00001) and 
EPCs (P<0.04) compared with non-serrated adenomas and 
CIAs. In addition, negative or low DCLK1 expression was 
significantly more frequent in SSA/Ps (92.3%) compared with 
TSAs (62.5%; P<0.05). High DCLK1 expression was more 
common in non-serrated adenomas (80.0%) compared with 
serrated polyps (19.4%; P=0.01). Furthermore, high DCLK1 
expression was more frequent in CIAs (75.0%) compared with 
EPCs (50.0%; P=0.10). Potential associations between protein 
expression and clinicopathological data (age, sex, tumor size, 
tumor location, macroscopic features, depth of invasion and 
lymphatic and venous invasion) were also analyzed; however, 
no significant associations were observed.
Discussion
The ACS and the serrated pathway are two distinct models 
that explain the development of colorectal neoplasms (3,23). 
Serrated colorectum polyps exhibit distinct histological 
features and malignant potential (3). CRCs arising from 
the serrated pathway are also frequently associated with 
aberrant patterns of promoter methylation (4), a phenotype 
discussed further below. Previous reports have suggested that 
DCLK1 may mark cancer stem cells in gastrointestinal and 
other cancers (10,24), while others have identified DCLK1 
upregulation in several types of cancer, including esophageal, 
stomach, colorectal, pancreatic and liver cancer (8,13-18). In 
addition, increased DCLK1 expression has been identified in 
Barrett's esophagus, a premalignant lesion that can progress 
to esophageal adenocarcinoma, and may be regarded as an 
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early molecular predictor of tumor progression (18). Although 
DCLK1 has been demonstrated to be upregulated in human 
colorectal adenoma and cancer (13), studies on the expression 
of DCLK1 in serrated tumor tissue are lacking. Thus, the 
present study was the first to demonstrate that DCLK1 protein 
was not overexpressed in serrated tumor tissues.
To the best of our knowledge, no study to date has 
compared DCLK1 expression levels in SSA/Ps, TSAs, 
non-serrated adenomas and adenocarcinomas. The present 
results indicate that negative or low DCLK1 expression is 
frequent in serrated neoplasias, particularly SSA/Ps, when 
compared with non-serrated neoplasias. Aberrant crypt foci 
in the right side of the colon, as a characteristic of MVHP, 
are a precursor lesion for the SSA/P-cancer sequence (22). 
In the present study, negative or low DCLK1 expression was 
detected in 23.1% of MVHPs. The serrated pathway involves 
widespread aberrant DNA methylation in promoter regions, 
a phenomenon termed CpG island methylator phenotype (4). 
As promoter methylation is commonly associated with 
transcriptional repression and subsequent reduction (or 
loss) of gene function, methylation at the DCLK1 promoter 
potentially explains the reduced expression observed in 
serrated polyps (6,25). Therefore, it is possible that DCLK1 
overexpression may serve a secondary role in this pathway. 
In addition, absent or low expression of DCLK1 was signifi-
cantly more frequent in SSA/Ps (92.3%) compared with 
TSAs (62.5%), indicating that each serrated tumor type has 
different molecular features.
Absent or low expression of DCLK1 in EPCs was frequent 
when compared with non-serrated adenomas and CIAs, and 
Figure 1. Representative results of DCLK1 immunostaining (brown). (A) Negative immunostaining in sessile serrated adenoma-polyp. (B) High DCLK1 
expression in traditional serrated adenoma. (C) High DCLK1 expression in a carcinomatous area of carcinoma in adenoma. (D) Negative immunostaining in 
early pure colorectal carcinoma without adenoma. Magnification, x200. DCLK1, doublecortin and CaM kinase‑like‑1. 
Table I. DCLK1 expression in early colorectal neoplasms.
 DCLK1 expression, n (%)
 ---------------------------------------------------------------------------------------------
Neoplasm type Sample size, n Negative or low High
GCHP   7 6 (85.7)a 1 (14.3)g
MVHP 13 10 (76.9)a 3 (23.1)g
TSA 16 10 (62.5)b 6 (37.5)g
SSA/Ps 26 24 (92.3)c 2 (7.7)g
Adenoma 20 4 (20.0)d 16 (80.0)h
CIA 20 5 (25.0)e 15 (75.0)i
EPC 18 9 (50.0)f 9 (50.0)j
a vs. d,e, P<0.0001; b vs. d,e, P<0.005; c vs. d,e, P<0.00001; f vs. d,e, P<0.04; b vs. c, P<0.05; g vs. h, P=0.01; i vs. j, P=0.10. DCLK1, doublecortin 
and CaM kinase-like-1; GCHP, goblet cell hyperplastic polyps; MVHP, microvesicular hyperplastic polyps; TSA, traditional serrated adenoma; 
SSA/Ps, sessile serrated adenoma/polyps; CIA, carcinoma in adenoma; EPC, early pure colorectal carcinoma without adenoma component.
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had an intermediate frequency between that of non-serrated 
adenomas/CIAs and serrated polyps, supporting the hypoth-
esis that the molecular pathogenesis of EPC is distinct from 
that of the ACS regarding the expression of DCLK1. EPCs may 
therefore contain tumors derived from the serrated pathway as 
well as the ACS.
In conclusion, in the early developmental stage of the 
serrated tumors, DCLK1 expression was infrequently detected, 
unlike the situation in ACS tumors. However, as the number 
of tumor samples in the current study was limited, further 
large-scale studies are now required to more precisely deter-
mine the role of DCLK1 in serrated tumorigenesis.
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